JP2011098965A5 - - Google Patents

Download PDF

Info

Publication number
JP2011098965A5
JP2011098965A5 JP2010250815A JP2010250815A JP2011098965A5 JP 2011098965 A5 JP2011098965 A5 JP 2011098965A5 JP 2010250815 A JP2010250815 A JP 2010250815A JP 2010250815 A JP2010250815 A JP 2010250815A JP 2011098965 A5 JP2011098965 A5 JP 2011098965A5
Authority
JP
Japan
Prior art keywords
weight percent
composition
pharmaceutically acceptable
spherical particles
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010250815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011098965A (ja
JP5866116B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011098965A publication Critical patent/JP2011098965A/ja
Publication of JP2011098965A5 publication Critical patent/JP2011098965A5/ja
Application granted granted Critical
Publication of JP5866116B2 publication Critical patent/JP5866116B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010250815A 2009-11-09 2010-11-09 嘔吐および下痢などの状態を解消または軽減するためのコーティングされた薬物球状体およびその用途 Active JP5866116B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25938709P 2009-11-09 2009-11-09
US61/259,387 2009-11-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015013685A Division JP5982020B2 (ja) 2009-11-09 2015-01-27 嘔吐および下痢などの状態を解消または軽減するためのコーティングされた薬物球状体およびその用途

Publications (3)

Publication Number Publication Date
JP2011098965A JP2011098965A (ja) 2011-05-19
JP2011098965A5 true JP2011098965A5 (enExample) 2013-12-19
JP5866116B2 JP5866116B2 (ja) 2016-02-17

Family

ID=43828063

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010250815A Active JP5866116B2 (ja) 2009-11-09 2010-11-09 嘔吐および下痢などの状態を解消または軽減するためのコーティングされた薬物球状体およびその用途
JP2015013685A Active JP5982020B2 (ja) 2009-11-09 2015-01-27 嘔吐および下痢などの状態を解消または軽減するためのコーティングされた薬物球状体およびその用途
JP2016025515A Pending JP2016094478A (ja) 2009-11-09 2016-02-15 嘔吐および下痢などの状態を解消または軽減するためのコーティングされた薬物球状体およびその用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015013685A Active JP5982020B2 (ja) 2009-11-09 2015-01-27 嘔吐および下痢などの状態を解消または軽減するためのコーティングされた薬物球状体およびその用途
JP2016025515A Pending JP2016094478A (ja) 2009-11-09 2016-02-15 嘔吐および下痢などの状態を解消または軽減するためのコーティングされた薬物球状体およびその用途

Country Status (11)

Country Link
US (2) US8524281B2 (enExample)
EP (1) EP2498751B1 (enExample)
JP (3) JP5866116B2 (enExample)
CN (4) CN102724962B (enExample)
AR (1) AR078951A1 (enExample)
AU (1) AU2010315362B2 (enExample)
CA (1) CA2780332C (enExample)
ES (1) ES2729677T3 (enExample)
NZ (1) NZ599762A (enExample)
TW (1) TWI429437B (enExample)
WO (1) WO2011056741A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108421044A (zh) 2005-02-03 2018-08-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimen comprising neratinib for the treatment of cancer
NZ599762A (en) 2009-11-09 2014-07-25 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
CN102675287A (zh) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
US9301957B2 (en) * 2011-11-14 2016-04-05 Novartis Ag Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
WO2025213381A1 (en) * 2024-04-10 2025-10-16 Hangzhou Jitai Pharmaceutical Technology Co., Ltd Neratinib-cyclodextrin composition and method for preparing same

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54119021A (en) * 1978-03-06 1979-09-14 Nippon Kayaku Co Ltd Carcinostatic agent
JPH0436237A (ja) * 1990-06-01 1992-02-06 Taiho Yakuhin Kogyo Kk 抗腫瘍性複合製剤
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
IL161921A0 (en) 2001-11-27 2005-11-20 Wyeth Corp 3-Cyanoquinolines as inhibitors of egf-r and her2 kinases
US20040122048A1 (en) * 2002-10-11 2004-06-24 Wyeth Holdings Corporation Stabilized pharmaceutical composition containing basic excipients
CL2004000016A1 (es) 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
AU2004266572A1 (en) 2003-08-01 2005-03-03 Wyeth Holdings Corporation Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050142192A1 (en) 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
EP3611273A1 (en) 2004-03-31 2020-02-19 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
JP5159303B2 (ja) * 2005-03-03 2013-03-06 武田薬品工業株式会社 放出制御組成物
DE602006012972D1 (de) 2005-04-28 2010-04-29 Wyeth Corp Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung
CN101180269A (zh) * 2005-05-25 2008-05-14 惠氏公司 制备3-氰基-喹啉的方法和由其制得的中间体
AR054833A1 (es) * 2005-07-15 2007-07-18 Wyeth Corp Formas de dosificacion de liberacion retardada oral altamemte biodisponibles de succinato de o-desmetilvenlafaxina
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
CN101300029A (zh) * 2005-11-04 2008-11-05 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
PL1948180T3 (pl) * 2005-11-11 2013-09-30 Boehringer Ingelheim Int Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
CN101340895A (zh) * 2005-12-22 2009-01-07 惠氏公司 包含替加环素的口服制剂
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
KR20090104862A (ko) 2007-01-12 2009-10-06 와이어쓰 정제내 정제 조성물
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009061349A1 (en) 2007-11-05 2009-05-14 Puretech Ventures Methods, kits, and compositions for administering pharmaceutical compounds
CN101185633A (zh) * 2007-12-14 2008-05-28 山东蓝金生物工程有限公司 一种治疗实体肿瘤的尼拉替尼缓释植入剂
CA2711558C (en) * 2008-01-04 2016-12-13 Intellikine, Inc. Phosphatidyl inositol-3 kinase inhibiting compounds
US20090246198A1 (en) * 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
WO2010048477A2 (en) 2008-10-24 2010-04-29 Wyeth Llc Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimen comprising neratinib for the treatment of cancer
RU2011152105A (ru) 2009-07-02 2013-08-10 УАЙТ ЭлЭлСи Составы таблеток 3-цианохинолина и их применение
US20120135952A1 (en) 2009-07-17 2012-05-31 Hanall Biopharma Co., Ltd. Butyric acid salt of n,n-dimethyl imidocarbon imidic diamide, method of preparing same, and pharmaceutical compositions and combinations containing same
WO2011008053A2 (ko) 2009-07-17 2011-01-20 한올바이오파마주식회사 N,n-디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
KR20110021691A (ko) 2009-08-25 2011-03-04 한올바이오파마주식회사 메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
KR101211227B1 (ko) 2009-08-25 2012-12-11 한올바이오파마주식회사 메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
KR101190953B1 (ko) 2009-08-25 2012-10-12 한올바이오파마주식회사 메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
NZ599762A (en) 2009-11-09 2014-07-25 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
FI4066821T3 (fi) 2009-11-09 2025-05-13 Wyeth Llc Neratinibimaleaatin tablettiformulaatioita
EP3575413A1 (en) 2009-12-11 2019-12-04 Wyeth LLC Phosphatidylinositol-3-kinase pathway biomarkers
CA2787048C (en) 2010-01-13 2021-06-22 Wyeth Llc A cut-point in pten protein expression that accurately identifies tumors and is predictive of drug response to a pan-erbb inhibitor

Similar Documents

Publication Publication Date Title
NZ599762A (en) Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
RU2370495C2 (ru) Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора
MX2022002952A (es) Formulaciones de liberacion modificada de 2-[3-[4-amino-3-(2-fluor o-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbo nil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrilo.
RU2008148547A (ru) Фармацевтические композиции, включающие дулоксетина гидрохлорид с замедленным высвобождением
CN105106203B (zh) 富马酸沃诺拉赞的药物组合物及其制备方法
CN102933573B (zh) 包含酰胺衍生物或其可药用盐的药物组合物
JP2007511510A (ja) 持続放出性ベンラファキシン製剤
TW200635618A (en) Solid dosage form comprising proton pump inhibitor and suspension made thereof
CN1301534A (zh) 稳定的缓释口服给药组合物
US9770437B2 (en) Compositions of eltrombopag
NO20081325L (no) Nye doseringsformuleringer
IE880901L (en) A crivastine containing composition
NO330144B1 (no) Gastrobeskyttede omeprazolmikrogranuler, fremgangsmate for a oppna slike og farmasoytiske preparater
WO2008067399A3 (en) Controlled-release multi-layer formulation of piperazine-piperidine antagonists and agonists of the 5-th1a receptor having enhanced intestinal dissolution
JPWO2017018473A1 (ja) 錠剤
RU2011152105A (ru) Составы таблеток 3-цианохинолина и их применение
RU2014129508A (ru) Новая комбинация
RU2007148195A (ru) Пероральные дозированные формы о-десметилвенлафаксин сукцината повышенной биодоступности с отсроченным высвобождением
WO2012150412A1 (fr) Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
TW201707702A (zh) 一種含有喹啉衍生物或其鹽的醫藥組成物
CA2471566A1 (en) Combination of mtp inhibitors or apob-secretion inhibitors with fibrates for use as pharmaceuticals
EA200600675A1 (ru) Гранулы, содержащие гидрохлорид венлафаксина
RU2401110C2 (ru) Препарат в форме пеллет с замедленным высвобождением для вертиго
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
AT393625B (de) Verfahren zur herstellung eines neuen therapeutischen praeparates enthaltend co-dergocrine und einen calciumantagonisten